General Information of Drug (ID: DM503DN)

Drug Name
1954U89 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
PubChem CID
177894
CAS Number
CAS 150057-49-1
TTD Drug ID
DM503DN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Trimethoprim DMM7CHK Acute otitis media AB00 Approved [2]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [2]
Leucovorin Calcium DMNWZJG Solid tumour/cancer 2A00-2F9Z Approved [3]
Methotrexate Sodium DM5XH2C Solid tumour/cancer 2A00-2F9Z Approved [2]
Iclaprim DM7YNV9 Bacterial infection 1A00-1C4Z Phase 3 [4]
PIRITREXIM DM276N1 Bladder cancer 2C94 Phase 2 [5]
CH-4051 DMLQRYH Rheumatoid arthritis FA20 Phase 2 [6]
MDAM (y-methylene-10-deazaaminopterin) DM1DISM Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
L-MDAM DMU901D Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
VYR 006 DMC9N7D Toxoplasmosis 1F57 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dihydrofolate reductase (DHFR) TTYZVDJ DYR_HUMAN Modulator [1]

References

1 The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. Biopharm Drug Dispos. 1997 Jul;18(5):433-42.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88.
6 CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67.
7 Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37.
8 Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12.
9 Clinical pipeline report, company report or official report of Vyera Pharmaceuticals.